| Biomarker ID | 995 |
| PMID | 23028830 |
| Year | 2012 |
| Biomarker | Ras-related GTP binding D (RRAGD) + polyglutamine binding protein 1 (PQBP1) +histone cluster 1, H2bg (HIST1H2BC)+ aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) +tripartite motif-containing 22 (TRIM22) + RNA binding protein with multiple splicing (RBPMS) + heat shock 22 kDa protein 8 (HSPB8) + Cell Type Hetrogenity + Gleason Score |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated: [histone cluster 1, H2bg (HIST1H2BC) (1.88 fold); polyglutamine binding protein 1 (PQBP1) (2.08 fold)]; Downregulated: [Ras-related GTP binding D (RRAGD) (0.45 fold); aldehyde dehydrogenase 1 family, member A2 (ALDH1A2) (0.49 fold) ; tripartite motif-containing 22 (TRIM22) (0.54 fold) ; RNA binding protein with multiple splicing (RBPMS) (0.49 fold) + heat shock 22 kDa protein 8 (HSPB8) (0.44 fold)] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | Biochemical relapse Vs No biochemical Relpase |
| Type of Biomarker | Prognostic |
| Cohort | Data Set 1 was used for training. It contains 136 post prostatectomy frozen tissue samples obtained from 82 subjects. The resulting Microarray data have been deposited in the GEO database: GSE8218. Out of the 136 samples, 80 samples were from biochemical relapsed patients, 50 samples from biochemical non-relapsed patients with follow-up from 3 to 80 months, and 6 samples from normal subjects. Data Sets 2 and 3 are independent test sets. Data Set 2 [GSE25136] contained 79 samples consisting of 42 bio- chemical non-relapsed and 37 biochemical relapsed samples. Data Set 3 [GSE3325] consists of 13 samples classified as 4 benign, 5 primary, and 4 metastatic prostate cancer samples. In the study, 4 benign and the 5 primary prostate cancer samples were treated as biochemical non-relapse samples and 4 metastatic prostate cancer samples as relapse samples. |
| Senstivity | Data Set 2: 76% ; Data Set 3: 75%; Data Set 2+3: 76% |
| Specificity | Data Set 2: 59% ; Data Set 3: 100%; Data Set 2+3: 65% |
| AUC | NA |
| Accuracy | Data Set 2: 69% ; Data Set 3: 86%; Data Set 2+3: 71% |
| Level Of Significance | p<0.002 |
| Method Used | Affymetrix + Immunohistochemistry (for cell type hetrogenity) |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |